BioNTech SE

BNTX

Company Profile

  • Business description

    BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.

  • Contact

    An der Goldgrube 12
    MainzRPD-55131
    DEU

    T: +49 613190840

    E: [email protected]

    https://www.biontech.de

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    7,807

Stocks News & Analysis

stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.
stocks

Chart of the Week: Anthropic’s IPO range sits below our fair value

Our fair value is above the IPO range, but outcomes could differ widely.
stocks

Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released

Several gaming shares are trading at a discount to our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,836.6095.80-1.07%
CAC 408,080.7466.09-0.81%
DAX 4025,463.81272.43-1.06%
Dow JONES (US)49,165.591,032.58-2.06%
FTSE 10010,452.6898.49-0.93%
HKSE22,841.62453.13-1.95%
NASDAQ23,911.90517.98-2.12%
Nikkei 22559,444.21419.930.71%
NZX 50 Index14,247.2517.04-0.12%
S&P 5007,185.87137.76-1.88%
S&P/ASX 2008,730.4091.40-1.04%
SSE Composite Index3,577.6210.21-0.28%

Market Movers